Lung CancersNCT07434167
Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
A study testing Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules in people with Lung Cancers and Metaverse, run by National Taiwan University Hospital.
Trial summary
Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lung Cancers, Metaverse, Extended Reality (XR)
- What is being tested?
- Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- Mar 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery.
- Patients with lung nodules smaller than 2 cm that require preoperative localization.
- Patients with lung nodules located in the outer one-third of the lung.
Who cannot join
- Patients requiring lobectomy.
- Patients who have not provided written informed consent.
- Vulnerable populations.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
Read the detailed description
The objective of this study is to investigate the safety and feasibility of extended reality (XR)-assisted computed tomography (CT)-guided localization of pulmonary nodules for preoperative tumor localization. The study aims to utilize a fully developed XR system to assist physicians in performing preoperative localization of pulmonary tumors, while also optimizing the workflow and efficiency of pulmonary nodule localization in a conventional CT suite.
This study plans to enroll 30 patients at our institution who are scheduled to undergo thoracoscopic sublobar resection. The safety and feasibility of using an XR-assisted digital twin model for pulmonary nodule localization in a standard CT suite will be evaluated.
- Conditions
- Lung Cancers, Metaverse, Extended Reality (XR)
- Being tested
- Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
- Keywords
- Metaverse, Extended Reality (XR), Digital Twin, Localization of Pulmonary Nodules, uniportal VATS
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extended Reality (XR)-Assisted CT Localization of Pulmonary NodulesProcedure or surgery
This study plans to collect approximately 30 localization cases from multiple centers within our institution. First, after patient positioning and immobilization in the computed tomography (CT) suite, a chest CT scan is performed. Imaging data are processed using semi-automatic segmentation and rapid reconstruction techniques to generate, in real time, a three-dimensional model that corresponds to the patient's current localization position.
During the construction of the three-dimensional model, patients remain in a fixed position. To reduce anxiety and discomfort associated with waiting, patient education related to pulmonary nodule localization and thoracoscopic surgery is provided during this period. The educational content includes the purpose of the procedure, procedural steps, potential risks, and key points of postoperative care. Once model construction is completed, a metaverse-based XR platform is used in the same setting to overlay the digital twin model onto the patient's
| Study group | Role | What they receive |
|---|---|---|
| Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules | Experimental | Not described Receives: Procedure: Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules |
What is being measured
The primary outcome is the main question the study is designed to answer.
Localization accuracy
Procedures in this study will be conducted in a CT room. The accuracy of XR-assisted CT-guided localization will be assessed immediately after localization by employing in-room CT to determine the needle tip position and measure the distance to the target tumor.
Measured: Immediatedly after Extended Reality (XR)-Assisted CT-Guided Localization
Secondary outcomes (1)
Assessment of perioperative outcomes
Perioperative outcomes, including intraoperative blood loss, localization time, operative time, and the rate of localization-related complications, will be measured. We will assess whether the incorporation of the localization system leads to reductions in these parameters.
Measured: The study assessment time frame from XR-assisted CT-guided localization to discharge is approximately 3 to 7 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study startMar 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancersStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07434167
- Sponsor's protocol ID
- 202601025RINB
- Status last verified
- Feb 2026
- First submitted
- 5 Feb 2026
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified individual participant data (IPD) collected during this study will generally not be shared with other researchers, primarily due to patient privacy considerations. However, limited access to de-identified IPD may be considered in exceptional cases upon a reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
- ClinicalTrials.gov ID
- NCT07434167
- Acronym / sponsor ID
- 202601025RINB
- Conditions
- Lung Cancers, Metaverse, Extended Reality (XR)
- Keywords
- Metaverse, Extended Reality (XR), Digital Twin, Localization of Pulmonary Nodules, uniportal VATS
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Mar 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules
Detailed description
The objective of this study is to investigate the safety and feasibility of extended reality (XR)-assisted computed tomography (CT)-guided localization of pulmonary nodules for preoperative tumor localization. The study aims to utilize a fully developed XR system to assist physicians in performing preoperative localization of pulmonary tumors, while also optimizing the workflow and efficiency of pulmonary nodule localization in a conventional CT suite.
This study plans to enroll 30 patients at our institution who are scheduled to undergo thoracoscopic sublobar resection. The safety and feasibility of using an XR-assisted digital twin model for pulmonary nodule localization in a standard CT suite will be evaluated.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules | Experimental | Procedure: Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery.
- Patients with lung nodules smaller than 2 cm that require preoperative localization.
- Patients with lung nodules located in the outer one-third of the lung.
Key exclusion criteria (3 listed)
- Patients requiring lobectomy.
- Patients who have not provided written informed consent.
- Vulnerable populations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extended Reality (XR)-Assisted CT Localization of Pulmonary NodulesThis study plans to collect approximately 30 localization cases from multiple centers within our institution. First, after patient positioning and immobilization in the computed tomography (CT) suite, a chest CT scan is performed. Imaging data are processed using semi-automatic segmentation and rapid reconstruction techniques to generate, in real time, a three-dimensional model that corresponds to the patient's current localization position. During the construction of the three-dimensional model, patients remain in a fixed position. To reduce anxiety and discomfort associated with waiting, patient education related to pulmonary nodule localization and thoracoscopic surgery is provided during this period. The educational content includes the purpose of the procedure, procedural steps, potential risks, and key points of postoperative care. Once model construction is completed, a metaverse-based XR platform is used in the same setting to overlay the digital twin model onto the patient's | Procedure or surgery | Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules |
Primary outcome
Localization accuracy
Time frame: Immediatedly after Extended Reality (XR)-Assisted CT-Guided Localization
Procedures in this study will be conducted in a CT room. The accuracy of XR-assisted CT-guided localization will be assessed immediately after localization by employing in-room CT to determine the needle tip position and measure the distance to the target tumor.
1 secondary outcome
Assessment of perioperative outcomes
Time frame: The study assessment time frame from XR-assisted CT-guided localization to discharge is approximately 3 to 7 days.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: No. De-identified individual participant data (IPD) collected during this study will generally not be shared with other researchers, primarily due to patient privacy considerations. However, limited access to de-identified IPD may be considered in exceptional cases upon a reasonable request.
Related trials for Lung Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules in people with Lung Cancers and Metaverse, run by National Taiwan University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xu-Heng Chiang (88672655136, lycansblueray@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Localization accuracy (time frame: Immediatedly after Extended Reality (XR)-Assisted CT-Guided Localization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.